Trillium Therapeutics Inc. Gains 44.66%
Thu 02 Jan 20 at 05:30 PM
Trillium Therapeutics Inc. (TRIL:NASDAQ) soared at $1.49, representing a gain of 44.7%. From Tue 10 Dec 19, the stock recorded 71.43% Up Days and 73.33% Green Days
About Trillium Therapeutics Inc. (TRIL:NASDAQ)
Trillium Therapeutics Inc is an immuno-oncology company developing therapies for the treatment of cancer. Its SIRPaFc and CD200 monoclonal antibody targets immuno regulatory pathways that tumor cells exploit to evade the host immune system.
Top 10 Gainers:
- Inpixon (INPX:NASDAQ), 201.83%
- DPW Holdings, Inc. (DPW:NYSEMKT), 101.65%
- Synthesis Energy Systems, Inc. (SES:NASDAQ), 100%
- Pulmatrix, Inc. (PULM:NASDAQ), 88.37%
- Outlook Therapeutics, Inc. (OTLK:NASDAQ), 48.31%
- Trillium Therapeutics Inc. (TRIL:NASDAQ), 44.66%
- Cassava Sciences, Inc. (SAVA:NASDAQ), 38.46%
- ToughBuilt Industries, Inc. (TBLT:NASDAQ), 37.45%
- Sophiris Bio, Inc. (SPHS:NASDAQ), 35.05%
- Aethlon Medical, Inc. (AEMD:NASDAQ), 29.8%